Nanotechnology Now - Press Release: Scientists Introduce New Contrast Agent to Detect Ovarian Cancer Cells

Home > Press > Scientists Introduce New Contrast Agent to Detect Ovarian Cancer Cells

Abstract:
New SPION-C595 contrast agent was introduced, designed and produced by Iranian researchers to detect and take images from ovarian cancer cells to be used in targeted magnetic resonance molecular imaging.

Scientists Introduce New Contrast Agent to Detect Ovarian Cancer Cells

Tehran, Iran | Posted on February 12th, 2014

Dr. Daryoush Shahbazi Gahrouyee, professor of medical physics in Isfahan University of Medical Sciences, explained about the research. "Magnetic nanoprobe that is super paramagnetic iron oxide nanoparticles (SPIONs-C959) bonded with folic acid was produced firstly. In this research, the new contrast agent (SPIONs-C595) was introduced, designed and produced to detect and take images from ovarian cancer cells to be used in targeted magnetic resonance molecular imaging."

"The compound was firstly prepared and then, toxicity tests and quality control tests were carried out, including studying hydrodynamic size changes of particles, magnetic properties and resting time. The performance of the designed nanoprobe was studied in its ability to be attached to cancerous cells under in-vivo and in-vitro conditions with taking MRI images, and the changes in the strength of imaging signal were investigated too. The produced compound had desirable stability and biocompatibility at in-vitro condition, to the extent that in the majority of concentrations and test times, the life duration of cells was reported to be higher than 80%," he said.

Resting time tests and concentration of iron at the level of ovarian cancer cells and MR images taken after the incubation of the cells with the synthesized nanoprobe and the commercial nanoparticles used in this study indicated much higher tendency of the attachment of the produced compound with the cellular level with high expression of C595 antigen. Although the performance of the nanoprobe was less than what expected under in-vitro conditions, in-vivo experiments confirm the higher tendency of the product for staying in tumor tissue in comparison with the commercial nanoparticles used in the research.

Results of the research have been published in details in The Scientific World Journal, 2013.

####

For more information, please click here

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: